SLG
ACAD icon

Stanley-Laman Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Stanley-Laman Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-13,946
Closed -$313K – 264
2018
Q1 		$313K Sell
13,946
-287,159
-95% -$7.95M 0.07% 236
2017
Q4 		$9.07M Buy
301,105
+157,229
+109% +$5.03M 1.96% 1
2017
Q3 		$5.42M Buy
+143,876
New +$4.68M 1.45% 14

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Stanley-Laman Group's ACAD Position: Q2 2018 in Review

Stanley-Laman Group sold out of Acadia Pharmaceuticals (ACAD) in Q2 2018, closing a stake of 13,946 shares — an estimated $313K sold.

Stanley-Laman Group first reported a position in ACAD in Q3 2017 and held it in 3 quarters. The position peaked at $9.07M in Q4 2017. 187 funds tracked by Wall St. Rank hold ACAD as of Q2 2018.

  • Stanley-Laman Group reported no remaining Acadia Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 13,946 Acadia Pharmaceuticals shares in Q2 2018, an estimated $313K.
  • Stanley-Laman Group first reported a position in Acadia Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Stanley-Laman Group's Acadia Pharmaceuticals position peaked at $9.07M in Q4 2017.
  • 187 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2018.

Based on Stanley-Laman Group's 13F filing for Q2 2018, filed 9 Aug 2018.